ARTICLE | Clinical News
DNX-2401 regulatory update
June 23, 2014 7:00 AM UTC
DNAtrix said FDA granted Fast Track designation to DNX-2401 to treat recurrent glioblastoma. DNX-2401 is in Phase I testing for recurrent malignant glioma and recurrent glioblastoma. The genetically m...